Specific Detection of Antibodies to Emerging and Established Arboviruses Including Zika Virus
Award amount
$224,958Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ImmPORT Therapeutics Inc dba Antigen Discovery Inc
- Proposal award date
- 2017-02-06
- Contract end date
- 2019-01-31
- UEI
- ZJAMPJY7M149
- Solicitation number
- PA16-302
- Topic code
- NIAID
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A sensitive and specific serology test for evaluating potency of whole cell Pertussis vaccines
- Optimizing immunogenicity of novel Cryptosporidium vaccine candidates
- SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections
- Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine candidates against Neisseria meningitidis
- Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
25 SBIR/STTR records share this UEI (2004–2025). Reported award amounts total $16,715,675. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services